Showing results (101-110 of 852) with videos related to
Sort By:
Pageof 86
International Journal of Cardiology. Congenital Heart Disease|June 15, 2026
Limited association between liver stiffness and clinical outcomes in Fontan-associated liver disease: a retrospective analysisLouise Cai, Preeti Choudhary, David Tanous, et al.Current Eye Research|August 28, 2010
Influence of non-toxic doses of bevacizumab and ranibizumab on endothelial functions and inhibition of angiogenesisAya Barzelay, Anat Lowenstein, Jacob George, et al.World Journal of Gastroenterology|May 12, 2020
Macrophages in metabolic associated fatty liver diseaseJawaher Alharthi, Olivier Latchoumanin, Jacob George, et al.Trends in Genetics : TIG|May 13, 2020
The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver DiseaseAli Bayoumi, Henning Grønbæk, Jacob George, et al.Expert Review of Gastroenterology & Hepatology|August 21, 2015
The benefits of exercise for patients with non-alcoholic fatty liver diseaseShelley E Keating, Jacob George, Nathan A JohnsonEuropean Journal of Pharmacology|June 17, 2009
Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic miceAdi Mor, Yoel Kloog, Gad Keren, et al.Seminars in Liver Disease|March 16, 2012
Exercise and the liver: implications for therapy in fatty liver disordersNathan A Johnson, Shelley E Keating, Jacob GeorgeEuropean Journal of Immunology|May 8, 2008
N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cellsAdi Mor, Gad Keren, Yoel Kloog, et al.Hepatology International|August 28, 2024
Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLDMingqian Jiang, Ziyan Pan, Jacob George, et al.Journal of Viral Hepatitis|July 16, 2026
Nationwide Socioeconomic Evaluation of Direct-Acting Antivirals for Chronic Hepatitis C Virus Infection in Japan Between 2014 and 2023Maito Suoh, Saeed Esmaili, Mohammed Eslam, et al.Pageof 86